Crossmark

EMA and FDA prune the checkpoint inhibitor treatment landscape

Crossref DOI link: https://doi.org/10.1038/s41585-018-0074-1

Published Online: 2018-08-16

Published Print: 2018-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Teo, Min Yuen

Rosenberg, Jonathan E.
License Information

Text and Data Mining valid from 2018-08-16
More Information

Article History

First Online: 16 August 2018

Competing interests

: J.E.R has received consulting fees from Genentech/Roche, AstraZeneca, Bristol-Myers Squibb (BMS), Seattle Genetics, Merck, Bayer, EMD Serono, Astellas, and Mirati Research; funding (for industry trials) from Genentech/Roche, Astellas, and Bayer; and research funding (investigator-initiated trial) from Novartis and Genentech/Roche. M.Y.T. has received research funding (IIT) from BMS.